Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 13/20 | 0.59 |
| ▸ | CCKAR | P32238 | 8/20 | 0.59 |
| ▸ | NOTCH1 | P46531 | 4/20 | 0.49 |
| ▸ | NOTCH3 | Q9UM47 | 3/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.49 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876987 | 1.00 | CCKBR (0.59) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL14876985 | 1.00 | CCKBR (0.59) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL14886969 | 1.00 | CCKBR (0.59) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL6005878 | 1.00 | CCKBR (0.59) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL6003659 | 0.94 | CCKBR (0.52) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL6005033 | 0.94 | CCKBR (0.52) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL6006097 | 0.92 | CCKBR (0.52) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL14886931 | 0.90 | CCKBR (0.57) | CCKBRCCKARNOTCH1NOTCH3RBPJ | |
| SCHEMBL6005603 | 0.90 | CCKBR (0.61) | CCKBRCCKARNOTCH1NOTCH3PSEN1 | |
| SCHEMBL6005796 | 0.88 | CCKBR (0.46) | CCKBRCCKARPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883502-B2 | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-11 | — | — | US | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| US-8377886-B2 | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-02-19 | — | — | US | claimed |
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-20240299462-A1 | ENDOCRINE CELLS THAT EXPRESS CHROMOGRANIN A | VIACYTE, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2023-09-07 | — | — | US | disclosed |
| WO-2014160413-A1 | IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS | VIACYTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140271566-A1 | IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS | VIACYTE, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014039908-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | disclosed |
| US-8377886-B2 | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120090043-A1 | TARGETS FOR RETROVIRUS ASSOCIATED DISEASES | UNIVERSITE DE LIEGE (BE) | 2012-04-12 | — | — | US | disclosed |
| WO-2012034101-A2 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20100222283-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DESEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2010-09-02 | — | — | US | disclosed |
| WO-2009035522-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DISEASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | CCKBR 4546/4885CCKAR 4716/4885NOTCH1 2/4885 |
| US-20230277574-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | CCKBR 4546/4885CCKAR 4716/4885NOTCH1 2/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | CCKBR 2482/4885CCKAR 3703/4885NOTCH1 2/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | CCKBR 2482/4885CCKAR 3703/4885NOTCH1 2/4885 |
| US-20100222283-A1 | USE OF GAMMA SECRETASE INHIBITORS AND NOTCH PATHWAY INHIBITORS FOR TREATMENT AND PREVENTION OF RENAL DESEASE | BACE1, GSAP, BACE2 | CCKBR 2971/4885CCKAR 3865/4885NOTCH1 12/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | CCKBR 4546/4885CCKAR 4716/4885NOTCH1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.